Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT). Note: The request metadata references "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Filing Type: Form 6-K (Report of Foreign Private Issuer) / ASX Appendix 3B (New Issue Announcement).
Reporting Period: January 2014, with the report signed and dated February 7, 2014.
Principal Executive Office: Level 2, 369 Royal Parade, Parkville, Victoria 3052, Australia.
Key Financial Metrics and Capital Structure
The filing details a specific capital raising event rather than providing a full period financial statement (e.g., revenue or profit).
- Securities Issued:
- Ordinary Shares: 3,928,900 shares issued via exercise of unlisted options (PBTAI) and 50,000 shares via exercise of unlisted options (PBTAW).
- Unlisted Options: 300,000 new options issued (100,000 fully vested; 200,000 vesting upon performance milestones).
- Consideration Received:
- Cash: AUD $884,003 (from 3,928,900 shares) and AUD $12,500 (from 50,000 shares).
- Non-Cash: Services provided under an Employee Service Agreement dated January 8, 2014 (for the 300,000 options).
- Exercise Price (Options): AUD $1.12 per option for the new issue.
- Total Quoted Securities: 422,659,996 Ordinary Shares (PBT) as of the filing date.
- Total Unlisted Options: 20,090,218 options across various classes.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or EBITDA) for the prior period. The material change reported is the increase in share capital and option pool resulting from the specific issuances detailed above:
- Capital Increase: Issuance of 3,978,900 new ordinary shares.
- Option Pool Expansion: Addition of 300,000 new unlisted options.
- Regulatory Compliance: The company utilized shareholder approval obtained on November 28, 2013, to issue 3,928,900 shares under Rule 7.3. The remaining 350,000 options were issued under an exception in Rule 7.2.
Guidance, Outlook, and Risks
Management Commentary: The filing is a statutory disclosure of a new issue and does not contain forward-looking guidance, revenue outlook, or management commentary on operational performance.
Risks and Contingencies:
- Performance Milestones: 200,000 of the newly issued options are contingent upon the achievement of performance milestones.
- Regulatory Warranties: The company warrants that the issue complies with the Corporations Act and that no "excluded information" exists that requires disclosure.
- Placement Capacity: The filing includes a calculation of remaining placement capacity under ASX Listing Rules 7.1 and 7.1A, indicating the company has significant remaining capacity (approx. 55.4 million shares under Rule 7.1 and 41.5 million under Rule 7.1A).
Important Facts for Investor Verification
- Company Identity: Verify that the investment target is Prana Biotechnology Limited (PBT), not Alterity Therapeutics Ltd, as the filing text confirms the former.
- Use of Proceeds: Confirm the specific allocation of the AUD $896,503 raised from option exercises and the nature of the services provided for the non-cash option grant.
- Dilution Impact: Assess the impact of the 3,978,900 new shares on existing shareholder ownership percentages.
- Option Vesting: Review the specific performance milestones required for the 200,000 newly issued options to vest.
- Regulatory Status: Confirm the company's compliance with ASX Listing Rules regarding the 15% placement capacity and the validity of the shareholder approval from November 28, 2013.